Hepalink Partners with Yongtai for U.S. Gabapentin Market

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H (HK:9989) has released an update.

Shenzhen Hepalink Pharmaceutical Group has entered a strategic distribution agreement with Zhejiang Yongtai Pharmaceutical to commercialize Gabapentin capsules in the U.S. market. This move aligns with Hepalink’s international expansion strategy, leveraging their established sales networks to tap into the $463 million U.S. market for Gabapentin. The partnership highlights Hepalink’s marketing capabilities and aims to boost its presence in overseas markets.

For further insights into HK:9989 stock, check out TipRanks’ Stock Analysis page.